

FAX completed form to ARJ (877) 451-8955 Intake Specialist (866) 451-8804 referral@arjinfusion.com arjinfusion.com/referrals

Infusion Therapy Patient Referral Form Patient Name: ____ DOB: _____ Primary Phone: _____ Work Phone: _____ SSN#: ___ State: ____ Zip: ___ City: Address: Primary Diagnosis: Please fill in appropriate ICD-10 code **Patient Information:** In order to service your patient and facilitate insurance authorization, please complete the following. Attach documents to FAX (see below) ☑ Copy of insurance card □ NKDA Allergies: ___ ☑ Patient demographics Wt: _____ lbs/kg Male □ Female □ __ in/cm ⊠ H&P Is this the first dose: Yes □ No □ If no, list product: Date of last infusion: Next dose due: ____ ☐ Other: Line type: ☐ PIV ☐ PICC ☐ Port ☐ Other: Lumen #: 2 Clinical Information: ARJ policies and protocols to be provided upon request. Medication Dose Directions Quantity/Refills Dispense: **☑** Product: Infuse IV per manufacturer guidelines **OR** 1 months supply on all selected medications Refill x12 months unless otherwise noted ☑ Reaction medications only to be dispensed if needed per ☑ RN to start peripheral IV or use existing CVC. RN to administer catheter flushing per ARJ Policy and Procedure manufacturer guidelines. ☐ **Premedication take 30 minutes prior to infusion** (*Note: If nothing is checked, no premeds will be given*) **Adverse Reaction Orders:** (Dispense 1 dose of each medication below to keep at pt home) In the event of an infusion reaction (ie: fever, chills, backache, headache, Diphenhydramine: 25-50 mg po **OR** 50 mg IV diluted in D5W or NS 50-100mL, infuse over 10-15 mins. rigors) the following orders will be followed and physician will be notified. OR Antihistamine: ☐ Fexofenadine 180 mg po ☐ Cetirizine 10 mg po Note: For mild reactions, patient may be treated and infusion Methylprednisolone: ☐ 125 mg slow IV push over 5 mins. **OR** ☐ _____ mg slow IV push over 5 mins. resumed at a slower rate. **STOP** infusion. Infuse D5W or NS at 20 mL/hr to keep line open, may Acetaminophen: □ 325-650 mg po **OR** □ _____mg po increase to 100-250 mL/hr for hydration. May give the following if stopping infusion does not resolve symptoms: □ D5W or NS 500mL - 1L IV over 30 minutes - 1 hour as tolerated daily PRN for hydration and/or headache **☑** Diphenhydramine ☑ RN to instruct patient to hydrate pre/post infusion. RN to instruct patient to take Diphenhydramine 50 mg IV diluted in D5W or NS 50-100 mL, infused over 10-15 minutes or 25-50 mg po and Acetaminophen 325-650 mg po every 4-6 hours for 24-48 hours as needed to prevent/treat 50 mg/10 mL NS IV push over 2-3 minutes, as tolerated. post infusion headache. 125 mg (**OR** _____ mg) slow IV push over 5 minutes. □ Other: ■ Acetaminophen ____mg) po at onset of symptoms. 325-650 mg (**OR** □ Ondansetron 4 mg slow IV push over 5 minutes or 4 mg ODT. **Epinephrine** pen by weight for use IM or SQ in anaphylactic reaction. May repeat one time. EMS/911 will be called if used. **3 Prescriber Information:** By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. ARJ Infusion Services has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services. Physician Name: _____ Office Contact: Address: _______City: ______ State: _____ Zip: ____ Phone: _____ Fax: _____

Physician Signature Required - Substitution Permitted

Physician Signature Required - Dispense as Written

Onfidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICITLY PROHIBITED. If you have received this message in error, please notify us immediately.

License #: NPI #: